IFRS operating profit vs Novel active substance launches
In 2025, IFRS operating profit worldwide was 10,330 million CHF; novel active substance launches was 79.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time in 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
IFRS operating profit
Unit: million CHF · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| Q1 2025 | Actual | 10,330 million CHF |
Novel active substance launches
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 79 |
Shared periods
Side by side
Only one period is published for both series. Comparing anything else would mean comparing different years.
| Period | IFRS operating profit | Novel active substance launches |
|---|---|---|
| 2025 | 10,330 million CHF | 79 |
Provenance
Where these numbers come from
IFRS operating profit
Operating profit determined under International Financial Reporting Standards.
2 observations in Global · source organisations: Roche
Novel active substance launches
Total number of novel active substances launched.
2 observations in Global · source organisations: IFPMA, IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring